Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Diabetes & metabolic syndrome - 16(2022), 8 vom: 31. Aug., Seite 102580 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kuchay, Mohammad Shafi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0SAC974Z85 |
|---|
| Anmerkungen: |
Date Completed 30.08.2022 Date Revised 19.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dsx.2022.102580 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344413357 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344413357 | ||
| 003 | DE-627 | ||
| 005 | 20231226022718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dsx.2022.102580 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344413357 | ||
| 035 | |a (NLM)35921765 | ||
| 035 | |a (PII)S1871-4021(22)00194-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuchay, Mohammad Shafi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2022 | ||
| 500 | |a Date Revised 19.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Canagliflozin |2 NLM | |
| 650 | 7 | |a 0SAC974Z85 |2 NLM | |
| 650 | 7 | |a Sodium |2 NLM | |
| 650 | 7 | |a 9NEZ333N27 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Misra, Anoop |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes & metabolic syndrome |d 2007 |g 16(2022), 8 vom: 31. Aug., Seite 102580 |w (DE-627)NLM189445564 |x 1878-0334 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:8 |g day:31 |g month:08 |g pages:102580 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dsx.2022.102580 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 8 |b 31 |c 08 |h 102580 | ||